1/30
12:00 pm
ipsey
Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program
Neutral
Report
Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program
1/29
01:00 am
ipsey
Ipsen nominates Peter Guenter to its Board of Directors
Neutral
Report
Ipsen nominates Peter Guenter to its Board of Directors
1/27
01:00 am
ipsey
Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team
Low
Report
Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team
1/21
11:45 am
ipsey
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
Neutral
Report
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
1/13
12:19 pm
ipsey
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
Neutral
Report
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
1/8
05:02 am
ipsey
IPSEN (OTCMKTS:IPSEY) was downgraded by analysts at UBS Group AG to a "neutral" rating.
Neutral
Report
IPSEN (OTCMKTS:IPSEY) was downgraded by analysts at UBS Group AG to a "neutral" rating.
12/22
01:00 am
ipsey
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
Low
Report
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
12/19
01:00 am
ipsey
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
Neutral
Report
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)